Jazz Pharmaceuticals plc (JAZZ) research
Jazz Pharmaceuticals plc- Sector
- Pharmaceuticals
- Last price
- $235.67
- As of
Jazz Pharmaceuticals plc (JAZZ): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-23.
As of . Source: SEC EDGAR filings for JAZZ. Method and limitations.
Share the JAZZ intelligence card
See the full JAZZ dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for JAZZ on one page. Preview it with sample data, then open it live with a free account.
Preview the JAZZ dossierActive signals for JAZZ
- highCONSENSUS_BUY
3 tracked funds increased JAZZ this 2026Q2, institutional consensus
- highinsider_cluster_sell
2 insiders at JAZZ sold $20.7M this week
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +62% to JAZZ (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 82% of JAZZ (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +2907% to JAZZ (2026Q2)
FREE, NO ACCOUNT
Every signal on JAZZ, as it fires
You are seeing 5 of 19 signals recorded on JAZZ since 2026-06-02.
The five above landed across 3 days. The other 14 were recorded on 3 other days. 13 of the 19 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in JAZZ (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP G50871105 · 2026Q2 | $242.6M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP G50871105 · 2026Q2 | $184.1M | 0.07% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP G50871105 · 2026Q2 | $135.4M | 0.19% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP G50871105 · 2026Q2 | $96.4M | 0.07% | , |
| D. E. Shaw & Co., Inc.CUSIP G50871105 · 2026Q2 | $21M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, JAZZ
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
JAZZ against its peers
JAZZ's operating margin of -10.1% ranks in the 39th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | JAZZ | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.3B USD | 815M USD | 67 | 22 |
| Gross margin | n/a | 52.5% | n/a | 8 |
| Operating margin | -10.1% | 7.2% | 39 | 18 |
| Net margin | -8.3% | 2.7% | 33 | 22 |
| Return on equity | -8.2% | 4.0% | 44 | 23 |
| P / E | n/a | 18.4x | n/a | 12 |
Peers (25): CORT, VTRS, AXSM, ZTS, AMRX, TEVA, LQDA, AMLX, TARS, OGN, SUPN, GSK, HRMY, GPCR, BHC, NKTR, TRVI, NUVB, BMY, XERS, ANIP, OCUL, INVA, PAHC, PFE. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (JAZZ: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more JAZZ signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to JAZZand get the insider, 13F, options, and confluence read in one view.